Sunitinib: 2/1 is superior to 4/2


Play all audios:

Access through your institution Buy or subscribe Sunitinib, an antiangiogenic agent, is the first-line treatment of metastatic renal cell carcinoma (mRCC); however, the adverse effects of


this treatment pose a problem for clinical management of many patients. Now, the newly published findings of a phase II clinical trial demonstrate that use of a 2/1 dosing schedule,


comprising 2 weeks of treatment followed by 1 week of rest, is superior to a 4/2 schedule in terms of both greater efficacy and fewer adverse events. Lead author Jae Lyun Lee explains the


rationale for this approach: “the first patient treated in our institution with the standard 4/2 schedule achieved a partial response after the first cycle, but he experienced severe adverse


events. The adverse events started to occur during weeks 2–3 and worsened during weeks 3–4.” This is a preview of subscription content, access via your institution ACCESS OPTIONS Access


through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink *


Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional


subscriptions * Read our FAQs * Contact customer support CHANGE HISTORY * _ 23 OCTOBER 2015 In the version of this article originally publshed online, there was an error in the fourth


paragraph; "reduced" should have read "improved". The corrected sentence is as follows: "Patients receiving sunitinib 2/1 had improved failure-free survival after 6


months of treatment...". This error has been corrected for the print and online versions. _ REFERENCES * Lee, J. L. _ et al_. Randomized phase 2 trial of sunitinib four weeks on and two


weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial. _Ann. Oncol._ 10.1093/annonc/mdv357 Download references Authors * Peter


Sidaway View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Sidaway, P.


Sunitinib: 2/1 is superior to 4/2. _Nat Rev Urol_ 12, 594 (2015). https://doi.org/10.1038/nrurol.2015.239 Download citation * Published: 22 September 2015 * Issue Date: November 2015 * DOI:


https://doi.org/10.1038/nrurol.2015.239 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative